Research programme: NADPH oxidase inhibitors - GenKyoTex

Drug Profile

Research programme: NADPH oxidase inhibitors - GenKyoTex

Alternative Names: GKT 831; GKT-03; GKT-136901; GKT-771; GKT-901; HTS programme; NOX inhibitors - GenKyoTex

Latest Information Update: 06 Jan 2017

Price : $50

At a glance

  • Originator GenKyoTex
  • Class Small molecules
  • Mechanism of Action CYBB protein inhibitors; NADPH oxidase inhibitors; NOX1 protein inhibitors; NOX4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Primary biliary cirrhosis
  • Research Cancer; Inflammation; Pain
  • No development reported Cardiovascular disorders; Diabetic nephropathies; Idiopathic pulmonary fibrosis; Neurodegenerative disorders

Most Recent Events

  • 23 Dec 2016 Preclinical trials in Primary biliary cirrhosis in Switzerland (unspecified route) before December 2016
  • 22 Dec 2016 Genkyotex plans a phase I trial for GKT 771
  • 22 Dec 2016 Genkyotex plans a phase II trial for Primary biliary cirrhosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top